Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Tuberculosis prevention must integrate technological and basic care innovation

Paul H. Mason, Tolu Oni, Maarten M.J.W. van Herpen, Anna K. Coussens
European Respiratory Journal 2016 48: 1529-1531; DOI: 10.1183/13993003.01449-2016
Paul H. Mason
1Centre for Values, Ethics and the Law in Medicine, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia
2Dept of Anthropology, Macquarie University, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul H. Mason
  • For correspondence: paul.mason@sydney.edu.au
Tolu Oni
3Division of Public Health Medicine, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten M.J.W. van Herpen
4Philips Africa Innovation Hub, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna K. Coussens
5Division of Medical Microbiology, Dept of Pathology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna K. Coussens
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Without societal, lifestyle and dietary innovations, new technologies will be ineffectual in stopping tuberculosis http://ow.ly/IgY3303bgdU

To the Editor:

Albert et al. [1] advocate for a multipronged approach in rolling out new diagnostic technology for tuberculosis (TB), stating “diagnostic tests alone, if not implemented with a comprehensive package of accompanying tools and within the context of a strengthened health system, may fail to demonstrate the expected benefit”. This is a lesson learned from those who have walked this path before us; one should not be too complacent to ignore basic strategies in the face of escalating technological advances in our field.

A telling example from the history of TB research and development serves as a potent reminder that technological innovation is ineffective in isolation. In 1917, due to the First World War, the Dutch company, Royal Philips, began developing X-ray equipment following supply chain cuts from Germany. Royal Philips eventually developed a portable X-ray capable of high-quality lung tissue images. In 1932, Royal Philips began TB screening among their staff, then their families, and eventually the entire populous of the city of Eindhoven (figure 1). This community-wide screening programme helped reduce TB rates in Eindhoven. By the 1940s, Eindhoven had less than half the TB incidence of cities like Amsterdam, Utrecht and Haarlem [2]. Remarkably, this dramatic reduction preceded the availability of antimicrobials. Treatment was a strict regimen of rest, diet, exercise and fresh air. Without lifestyle and dietary innovations, new diagnostic technologies such as radiography would have been ineffectual in controlling TB.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

A speech by Anton Philips to celebrate the 100 000th radiograph scan for tuberculosis, on May 4, 1939. Figure reproduced with permission from the Philips Company Archives.

A hundred years on, the global TB epidemic persists and the innovative research and development community is struggling to deal with the increasing prevalence of drug-resistant TB. This calls for a re-visit to these basic innovations, with a greater focus on prevention of acquisition of infection and progression from latent to active disease. Whilst there are parallels between the TB epidemics of a hundred years ago and the present day, a significant difference is the nature of epidemiological transition and rapid urbanisation, driving the coexistence of infectious and non-communicable diseases, now occurring particularly in low- and middle-income countries. Basic and integrated innovations that address shared risk factors for TB and emerging non-communicable diseases are needed to improve overall health profiles. Nutritional and behavioural innovations that address exposures such as alcohol abuse, tobacco smoke, cooking fuels, diabetes and vitamin D deficiency, in addition to interventions in the built and natural environment, are going to become even more important. Clinicians at the frontlines of TB care in the developing world are often left trying to implement antimicrobial therapy in contexts of dense urban overcrowding, food insecurity and air pollution. Population growth and climate change are further exacerbating the global TB burden. Rolling out technological innovations in the absence of adequate nutrition and basic patient support services could very well serve the rise of drug-resistant TB.

In the contemporary TB research landscape, “innovation” has become almost synonymous with vaccine, biomarker and drug discovery. However, any of these technological innovations will require appropriate implementation within the context of the community they are targeted at. The coexistence of a variety of underlying morbidities, each an independent risk factor for TB, also indicates that the research community developing new technologies must test these technologies in a variety of populations and co-morbidity backgrounds. Despite this need for understanding the inter-relationship of co-morbidities, interventional research studies often exclude the majority of these individuals who are most at risk. This includes pregnant women and children, and persons with diabetes and HIV infection. Often-insufficient demographic information is captured to analyse the effect of contextual factors such as alcohol abuse, smoke exposure, and nutritional deficiencies on research outcomes. If taken into account, an integrated treatment approach addressing nutritional, behavioural and social interventions together with the new technology could then be assessed.

New technology alone cannot solve the TB epidemic. Innovative, integrated and community-driven solutions, which apply a primary health care approach, and are not purely based on technological innovation, will be required to stop the persistence of TB.

Footnotes

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received July 20, 2016.
  • Accepted August 7, 2016.
  • Copyright ©ERS 2016

ERJ Open articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Albert H,
    2. Nathavitharana RR,
    3. Isaacs C, et al.
    Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J 2016; 48: 516–525.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Eindhoven Vooraan in de Strijd Tegen T.B.C., Koerier, 15 May 1948.
PreviousNext
Back to top
View this article with LENS
Vol 48 Issue 5 Table of Contents
European Respiratory Journal: 48 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tuberculosis prevention must integrate technological and basic care innovation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Tuberculosis prevention must integrate technological and basic care innovation
Paul H. Mason, Tolu Oni, Maarten M.J.W. van Herpen, Anna K. Coussens
European Respiratory Journal Nov 2016, 48 (5) 1529-1531; DOI: 10.1183/13993003.01449-2016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Tuberculosis prevention must integrate technological and basic care innovation
Paul H. Mason, Tolu Oni, Maarten M.J.W. van Herpen, Anna K. Coussens
European Respiratory Journal Nov 2016, 48 (5) 1529-1531; DOI: 10.1183/13993003.01449-2016
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Latent COPD: a proposed new term in the disease nomenclature
  • Anti-anaerobic antibiotics: indication is key
  • Reply: Anti-anaerobic antibiotics: indication is key
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society